Economic Factors Amplify Burden of Disease for Patients With Multiple Sclerosis

Sept 2019

While economic issues differ across countries and healthcare systems, a universal concern is that Multiple Sclerosis (MS) is a costly disease that exerts a significant burden on patients, families, and society as a whole. 

Speaking at the ECTRIMS 2019 Congress in Stockholm, health economist Gisela Kobelt, PhD, MBA, described concepts associated with economic burden in MS. 

"disease burden for people with MS is related to reduced quality of life through physical suffering, limitations imposed on daily life, loss of work, and anxiety about the future." Economic factors may include loss of income for the patient, care-giving time for the family, and societal costs, which include burden on the healthcare system due to high healthcare utilization.
Not surprisingly, the evidence shows that the burden of disease in MS increases with a patient's level of disability. As the disease progresses, quality of life declines sharply, she explained, but costs increase. "Our aim, therefore, is to try to change the slope of this curve and delay the time it takes for patients to become severely disabled."
Dr. Kobelt presented observational data from the European Burden of Illness Study, a cross-sectional study involving 16,808 people with MS from 16 countries (mean age was 51.5 years, 52% had relapsing MS). Participants reported on their disease, its impact on health-related quality of life, and consumption of healthcare resources. The goal of the study, Dr. Kobelt said, was to assess whether MS management approaches provide value to society. Some of the findings:
Work capacity declined from 82% to 8%;Utility declined dramatically from normal levels to less than zero with advancing disease. (In health economics, utility is a quality of life measure in which 0 represents death and 1 represents perfect health);Fatigue was reported by 95% of participants and cognitive difficulties by 71%; both had a significant independent effect on utility;Costs increased by 6-fold for those with the highest level of disability compared with the lowest level.
Previous work by Dr. Kobelt showed that the greatest effects of MS on employment occur at relatively low levels of physical disability. This underscores the report’s recommendation of aiming to alter the disease course through lifestyle measures and early treatment with disease-modifying therapy. "The time to intervene is obviously at the beginning," Dr. Kobelt stressed. "We are not gaining much if we start when disease is advanced or the costs are already high. We really want to intervene early to achieve gains in quality of life and potential cost savings."

Article Source



This Article is Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  55 Hits

Copyright

© M.S. Views & News

55 Hits

Genentech Presents New Six-Year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis


SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
– Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients needing a wheelchair after six and a half years of Ocrevus treatment compared with patients who started Ocrevus after the double-blind period –
– Interim analysis of Phase IIIb study shows 87% of patients with suboptimal response to previous treatment had no evidence of disease activity one year after switching to Ocrevus –
– Separate analysis from same study showed greater patient satisfaction with Ocrevus after one year on treatment –
– More than 120,000 people have been treated with Ocrevus globally, in clinical trial and real-world settings; data continue to show a consistent and favorable benefit-risk profile –
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed that patients who were treated with Ocrevus® (ocrelizumab) continuously for six years or more had reduced risk of disability progression in relapsing MS (RMS) and Primary Progressive MS (PPMS). These results suggest earlier treatment with Ocrevus reduced the risk of disability progression and this effect was sustained over time. Additionally, new safety data as of January 2019 were announced, representing 4,611 patients with RMS and PPMS and 14,329 patient years of exposure to Ocrevus, across all Ocrevus clinical trials, and remain consistent with the medicine’s favorable benefit-risk profile. Findings were presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm.
“The effect of MS therapies on progression – not just relapses – is very important to help reduce the impact of the disease on the daily lives of people with MS and their families,” said Professor Gavin Giovannoni, Consultant Neurologist at Barts and the London School of Medicine and Dentistry. “The Ocrevus data at ECTRIMS highlight that the benefit of delaying, and possibly preventing, disability progression is greater when the treatment is used earlier in the disease course for both relapsing and Primary Progressive forms of MS. These data support the aphorism, ‘time really is brain and spinal cord in Multiple Sclerosis.'”
In the OPERA OLE, the proportion of RMS patients with 24-week confirmed disability progression (CDP) was lower for those treated with continuous Ocrevus (total of six years on Ocrevus) compared with patients who switched to Ocrevus after two years of interferon beta-1a treatment in the double-blind period (total of four years on Ocrevus) (19% vs. 24%; p
Original author: Stuart
  56 Hits

Copyright

© M.S. Views & News

56 Hits

Genentech’s Satralizumab Significantly Reduced Relapse Risk in Second Positive Phase III Study for Neuromyelitis Optica Spectrum Disorder

Pivotal Phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at ECTRIMS Congress 2019

74% reduction in the risk of relapse for satralizumab monotherapy versus placebo in people with neuromyelitis optica spectrum disorder (NMOSD) with aquaporin-4 antibodies (AQP4-IgG seropositive patients) Satralizumab demonstrated a similar safety profile compared to placebo in two Phase III studies across a broad population Satralizumab targets the interleukin-6 (IL-6) receptor, a key driver of NMOSD

South San Francisco, CA -- September 11, 2019 --
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today full pivotal Phase III study results for satralizumab as a monotherapy for neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating central nervous system disease. Results from the SAkuraStar study, presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), show that satralizumab monotherapy achieved a 55% reduction in the risk of relapses compared to placebo in the overall population, representative of NMOSD patients (Hazard Ratio [HR]=0.45, 95% Confidence Interval [CI]: 0.23-0.89; p=0.0184). In the large (~67%) subgroup of patients seropositive for AQP4-IgG antibodies, the effect was higher with a 74% reduction in risk of relapses (HR=0.26, 95% CI: 0.11-0.63; p=0.0014). People who are AQP4-IgG seropositive tend to experience a more severe disease course.
“The positive Phase III results for satralizumab, first as an add-on therapy and now as a monotherapy, are exciting to see, and importantly, satralizumab achieved efficacy in a broad range of NMOSD patients, reflective of what we see in our everyday practice. Satralizumab targets the IL-6 receptor, potentially offering a novel treatment approach,” said Professor Jeffrey Bennett, University of Colorado Neurology & Ophthalmology. “Approved treatment options demonstrating favorable safety and efficacy in controlled clinical trials are urgently needed. Even one relapse may lead to blindness and debilitating motor dysfunction for people with NMOSD.”

continue


........................................................................................................
This Article is Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  68 Hits

Copyright

© M.S. Views & News

68 Hits

Music Therapy for MS: How Rhythm Can Help With Movement and Memory

Music and rhythm can improve the brain’s ability to function and the body’s ability to move.
By David Spero, RN
Medically Reviewed by Samuel Mackenzie, MD, PhD


Have you found yourself clumsier or less coordinated since you developed Multiple Sclerosis (MS)? Is your walking affected?

One approach that may give you your rhythm back is music therapy — a type of therapy that uses music to address physical, emotional, cognitive, or social needs of individuals.

How can music help with MS? Barbara Seebacher, PhD, a physiotherapist based in Innsbruck, Austria, explains:

“There are three different brain centers responsible for the timing of movement: the motor cortex, the basal ganglia, and the cerebellum. One or another of these can be damaged by stroke, Parkinson’s disease, or multiple sclerosis.”

Music can often supply the timing that has been damaged, helping your body to work more smoothly.

Neurological music therapist Brian Harris, a founder of MedRhythms in Boston, says, “When you hear a rhythm, a song, or a metronome, it activates the auditory system, which activates the motor system at a subconscious level.”

This process is called “entrainment.” Harris says, “The rhythm is telling your brain to tell your body to move. For people who have damage to the brain, using rhythm can engage undamaged areas to help people move. We have quantifiable data on this. People walk faster; they have longer strides. You can see the changes on neurological imaging.”
Read on


........................................................................................................
This Article is Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  50 Hits

Copyright

© M.S. Views & News

50 Hits

How MS Affects Sleep Quality - Plus: Sleep Tips for People with Multiple Sclerosis

How MS Affects Sleep Quality - Plus: Sleep Tips for People with Multiple Sclerosis
Article originally published on Mattress Advisor

Do you ever feel like your energy levels disappear during the day? If so, you’re not alone. One of the hardest parts of living with Multiple Sclerosis (MS) is fatigue.
MS fatigue is unique. Instead of the typical “tired” feeling that the general population might feel when they didn’t sleep much, MS fatigue is more all-encompassing. While daytime sleepiness is usually part of it, you might also experience:
·       Brain fog
·       Trouble thinking
·       Confusion
·       Physical weakness
·       Memory difficulties
SO, WHAT CAUSES THIS FATIGUE?
While researchers once thought it was mainly disease progression, a recent study has found that there are other factors that are stronger predictors…and one of them is the presence of sleep disturbances.
Sleep and MS have a complicated relationship. When you have MS, it can be harder to sleep. On the flip side, when you don’t sleep well, your MS symptoms can be more severe.

With 50% of people with MS reporting sleep disturbances, understanding how sleep and MS relate is the first step towards reducing MS fatigue. Read on to learn more about how MS and sleep interact and what you can do to take back control.
How MS Affects Sleep Quality
Multiple Sclerosis can have a negative impact on sleep quality. As the disease progresses, there are many changes that can cause sleep disturbances. These include:
1.      Pain: Chronic pain can make every aspect of sleep challenging. It can make it hard to fall asleep and sleep soundly throughout the night.
2.      Medications: Some MS medications have side effects that impact sleep.
3.      Frequent urge to urinate: It’s not uncommon for MS patients to experience an increased need to urinate. During the nighttime, this can lead to waking up frequently during the night.
4.      Muscle spasticity: Muscle spasms in the arms and legs can interrupt sleep and make it hard to fall asleep.
5.      Stress: Anxiety and chronic stress can happen as patients learn to cope with disease symptoms.
6.     Depression: Depression is common in MS patients, and it can also lead to trouble sleeping.
7.      Sleep disorders: Many sleep disorders are more common in MS patients than in the general public. These are often caused by MS progression.
8.      Brain lesions: MS can lead to brain lesions in regions that impact sleep.
9.     Poor temperature regulation: Some patients can experience difficulties regulating temperature. As our sleep/wake cycle is tied to body temperature changes, this can lead to insomnia.
10.  Poor sleep schedule: Daytime napping is often necessary to fight fatigue, but too much napping can make sleeping during the nighttime difficult.
As MS progresses, nerves aren’t able to communicate as well with one another. Body processes like hormone and neurotransmitter release can be impacted, resulting in many of the above sleep disturbance contributors.
Does Sleep Deprivation Make MS Worse?
In MS patients, sleep problems and symptom severity are tied. Unfortunately, not getting enough sleep can exacerbate MS symptoms. This is particularly true of daytime fatigue, which is very common in MS patients and whose primary causes are believed to be depression and sleep disturbances.
Sleep Tips for People with Multiple Sclerosis
Getting enough sleep is critical to improving symptoms like fatigue, depression, memory difficulties, stress, and more. While getting quality sleep can be a challenge with MS, there are many things that you can do to improve your quantity and quality of sleep.
Relax Before Bed
After a challenging day, it can be hard to turn off our thoughts and worries and fall asleep. Rather than worrying about tomorrow or stressing about what happened today, do what you can to calm your mind and let go of your stress.
Some great options include meditation or breathing exercises. Both of these have been shown to help reduce stress and lessen the amount of time that it takes to fall asleep.
Stop Drinking Before Bedtime
Waking up in the middle of the night because you need to run to the bathroom can be frustrating…particularly if you find falling asleep afterward difficult. If you find yourself running to the bathroom in the middle of the night, you might want to stop drinking for two hours or more before bedtime.
Set a Sleep Schedule
It can be helpful to go to bed at the same time every day. This bedtime routine helps to keep your body’s internal clock, known as its circadian rhythm, functioning properly. Additionally, try to go to sleep when it’s dark out and wake up around sunrise or a little after to avoid future sleep issues.  
Exercise During the Day, But Not at Night
Moderate exercise on a daily basis can help you sleep better while helping your mood and health. One thing to note: exercise shortly before bed can make it harder to fall asleep. Avoid working out three hours or more before bedtime.
Limit Alcohol and Caffeine
Both alcohol and caffeine can disrupt your natural sleep/wake cycle and make getting quality sleep hard to do. If you’re going to have caffeine, try to stop drinking it around midday. As for alcohol, the less the better. Even one or two drinks before bedtime can reduce how much deep sleep you achieve, and it can exacerbate sleep disorders like sleep apnea.
Prepare Your Room for Sleep
In order to sleep soundly throughout the night, there are a few things that you will want to take care of. First, be sure to limit distractions. This might mean having pets sleep outside of your bedroom and turning your phone to airplane mode, so you don’t get interrupted while you sleep.
Next, control the sound and light in your room. If ambient light comes through your windows, use dark curtains or blackout shades to limit it. If you find that noises wake you up at night, try a white noise machine to drown out outside noise.
Limit Light Exposure Before Bedtime
Humans are sensitive to light. When we’re exposed to excess blue light at night, it can throw off our natural sleep/wake cycle, resulting in difficulties falling asleep. Electronics are particularly high in blue light, so try not to watch TV or use your computer or smartphone for an hour or more before bed.

Multiple Sclerosis and sleep can be a challenging combination, but learning how to sleep well when you have MS is incredibly important for your happiness, health, and overall quality of life.

When you find yourself excessively sleepy during the day or struggling to get a good night’s sleep, talk to your doctor. Whether your fatigue is due to sleep troubles or something else, they can help you come up with a plan.


...................................................................................

Stay Informed. Register to receive 
Important MS News and Views:  Click here

.................................................................................................


..................................................................................................
This Article is Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  72 Hits

Copyright

© M.S. Views & News

72 Hits

Sleep and Mental Health: Why Our Brains Need Sleep

Understanding how sleep impacts the mind and the link between sleep disorders and mental illness.

IN THIS ARTICLE

How Sleep Impacts Mental HealthSleep Deprivation and Our Psychological StateEmotional InstabilityHormone DisruptionMental Illness and SleepAnxietyDepressionADHD

Sleep for the brain is like gas for a car. When the tank is full we get where we need to be. But as time goes on, the gauge falls lower and lower until the gas is gone and the car stops. Without the fuel it needs, the car is useless.

Our brains operate in a similar way. The only difference is the brain’s fuel is sleep. Without proper sleep, our minds begin to slow, unable to operate at their full potential. This happens until the mind becomes so deprived of the rest it needs, it breaks down. And without the commander-in-chief acting accordingly, the rest of the body pays the price.

In this guide, we are going to deep dive into the complex relationship between sleep and mental health, including how these two aspects of health are inversely related, the consequences of sleep deprivation on the mind, and the link between sleep disorders and mental health disorders.

You ready? We’re really about to exercise your mind.

Click here to continue reading




This Article is Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  51 Hits

Copyright

© M.S. Views & News

51 Hits

Central Michigan Hospital plots leadership path in MS research (Blood testing for MS, NeuroFilaments and more)

Memorial Healthcare's neurology department is growing and engaged in cutting-edge research
New blood tests for MS patients are being tested that will help doctors pinpoint stage of disease and best drug to slow debilitating effects
Multi-disciplinary team approach cuts testing and diagnosis process to one day
Rany Aburashed, D.O.
Neurologist Rany Aburashed, D.O., is leading Memorial Healthcare's clinical renaissance and putting it on the map nationally by pioneering clinic-based research on a new blood test for Multiple Sclerosis on thousands of patients.
Memorial Healthcare, a small 161-bed rural referral center in central Michigan, is believed to be the only hospital in the U.S. where the Simoa Analyzer MS blood test technology is being tested, Aburashed said. There are about 100 universities that are testing the MS blood test technology on animals, experts said.
Aburashed also has helped to create Memorial's Institute Institute for Neurosciences and Multiple Sclerosis that offers patients a multi-disciplinary approach to MS care that is in effect, "one-stop shopping" for co-located neurology, orthopedics, rehabilitation and wellness programs.
"The Europeans tend to be ahead of us in terms of research into MS. They are much more aggressive after the disease and treatment," Aburashed said. "When we saw more and more evidence from the European data on neurofilaments that was not only predictive of MS but also was predictive of (how effective is the) drug working. I realized this was going to the future of MS care over the next five years and we had to have it."
While the MS blood test using "neurofilament light chain" technology, or NfL, is still under clinical trials in the U.S. and not approved by the U.S. Food and Drug Administration, it is also widely being researched in Europe.
The blood test detects NfL, a structural protein that forms part of the internal skeleton of neurons. When brain neurons are damaged or dying, the protein leaks out into the fluid that covers the brain and spinal cord. From there, the brain and spinal fluid goes into the bloodstream.
By hard work and determination, Aburashed earlier this year won approval from the hospital's institutional review board to test the NfL technology in a five-year trial. He also was able to secure the machine to test NfL, the Simoa Analyzer, from Quanterix Corp, a Billerica, Mass.-based biotech company.

This Article is Provided by:  #MSViewsandNews
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  214 Hits

Copyright

© M.S. Views & News

214 Hits

Social Cognition: Does It Impact MS Symptoms?

SEPTEMBER 6, 2019 - BY ED TOBIAS

Feeling tired, depressed, or anxious? Maybe it has to do with your social cognition. Social cognition involves empathy and recognizing the emotions that are revealed by someone’s facial expression. That expression may show fear or disgust. Or it may warn us of danger.

Social cognition also involves the theory of mind. This has to do with beliefs, and with a person understanding that others may have beliefs and perspectives different from their own. It is considered important for daily social interactions because everyone uses it, subconsciously, to judge and understand the actions and behaviors of other people.

Social cognition and MS

There is evidence that people with MS have a hard time with social cognition. Now, a small study run by the Kessler Foundation has looked at how those social cognition problems might have an impact on some of our MS symptoms. Test subjects who performed poorly on social cognition tasks self-reported that they had worse depression, anxiety, and fatigue than those with better test scores.
But what comes first? Do social cognition problems exacerbate MS symptoms, or do the symptoms create social cognition problems?
“The nature of the relationships among these variables remains unclear,” says Helen Genova, PhD, the study’s lead writer. “We cannot say whether deficits of social cognition worsen mood condition and fatigue, or vice versa. … Poor social cognition may worsen fatigue, depression, and anxiety, leading to greater social isolation. That, in turn, may worsen social cognitive function.”
It seems to me that someone who has a hard time picking up social cues would be someone who is depressed and anxious. If you can’t easily determine the mood of another person, it is hard to make a personal connection with that person. I’d think that would lead to difficult relationships and a very small circle of friends. Genova seems to agree with my assessment.
“All of these conditions adversely affect quality of life,” she says.
So, it looks as if the best we can do is add social cognition to the list of difficulties for those of us with MS. Being aware of that may help us cope.
article source


This Article is Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  12 Hits

Copyright

© M.S. Views & News

12 Hits

My Disabled Wheelchair

My Disabled Wheelchair
AUGUST 30, 2019 - BY JOHN CONNOR

Things had been going well with my electric wheelchair, but now I found myself out of control, heading toward the TV. I put my one good foot down in a feeble attempt to delay what seemed inevitable. Somehow, the foot — or perhaps sheer good luck — saved the TV. I stopped a foot away!
The left armrest of my newish ‘leccy wheelchair had just fallen off, taking the chair controls with it. I was a passenger on a runaway wheelchair! This was excitement I could do without, especially as it was late and a scream would wake the house.
I was only a yard away from my bed, but it might as well have been a mile. There was no way I’d make it. My phone and sticks were also inconveniently out of reach.
As this situation could have been a lot worse, I took a moment to calm myself.
Disabled wheelchair (Photo by John Connor)
Luckily, my trusty wheeled commode looked reachable. Before I’d gone electric, I’d actually used this as my main means of locomotion around the house for a year. I was no longer much good with a self-propelling wheelchair, but by using a stick like an oar and pushing with my left foot, I could actually get somewhere. True, I was better at going backward. Since MS has turned my life around, this seemed somehow apposite.
I managed to transfer without crashing to the floor, so that was a win.
Luckily, the wheelchair is from the NHS and there’s a service company I can call. (I’ve actually written disparagingly about this company in the past.) I sent them a late-night email and followed up with an early-morning call.
Much to my pleasant astonishment, a technician turned up about an hour after my morning call and tightened the nuts that secured both armrests to the base of the wheelchair — they had worked themselves loose. Up to now, I’d actually presumed the exaggerated in-and-out movements were just a nifty design feature. Sure, I could have read the manual in detail, but who actually does that?
The armrests are supposed to be solidly fixed. The tech said he’d seen the same thing in about five new wheelchairs of the model I use, an Invacare Bora/Spectra XTR Series.
It only took him five minutes to fix.
Crisis over? Not quite.
Within a few days, the armrests loosened again. They’re not yet as bad as they were before, but I immediately booked the technician. Since it’s not urgent this time, he’s coming around tomorrow. He did nothing wrong. He’d tightened as fast as he could without breaking the nuts.
It must be a manufacturing flaw.
Somewhat ironically, I seem to have a disabled wheelchair!
***
...................................................................................

Stay Informed. Register to receive 
'The MS BEACON' e-Newsletter Click here


::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  13 Hits

Copyright

© M.S. Views & News

13 Hits

Assessment and Measurement of Spasticity in MS: State of the Evidence.

Author information

1Department of Neurology, Oregon Health & Science University, 3303 SW Sam Jackson Park Rd., L226, Portland, OR, 97239, USA. This email address is being protected from spambots. You need JavaScript enabled to view it. Portland Health Care System, 3710 SW US Veterans Hospital Rd., R&D 27, Portland, OR, 97239, USA. This email address is being protected from spambots. You need JavaScript enabled to view it.t of Neurology, Oregon Health & Science University, 3303 SW Sam Jackson Park Rd., L226, Portland, OR, 97239, USA.4VA MS Center of Excellence-West, VA Portland Health Care System, 3710 SW US Veterans Hospital Rd., Portland, OR, 97239, USA.

Abstract

PURPOSE OF REVIEW:

The purpose of this review is to familiarize the reader with assessments and measurement of spasticity in people with Multiple Sclerosis (MS). Spasticity affects 60-84% of people with MS, Worsening as disability worsens and impacting activity, participation, and quality of life. Spasticity manifests in many ways, including spasms, resistance to passive stretch, pain, and perception of tightness, and can affect muscles throughout the body, making assessment and quantification of spasticity challenging but important. Assessment tools include those quantified by clinicians, instrumentation, and patients.

RECENT FINDINGS:

Most tools for measuring spasticity are based on clinician scoring, were developed many years ago, and have undergone minimal recent advances. More recent developments are patient-reported outcome measures for spasticity, including the Numeric Rating Scale for Spasticity (NRS-S) and the disease-specific Multiple Sclerosis Spasticity Scale-88 (MSSS), and, most recently, imaging through elastography. MS-related spasticity is common and often disabling. There are various spasticity measurement tools available, each with advantages and limitations. Newer tools are likely to be developed as our understanding of spasticity in MS grows.

KEYWORDS:

Assessment; Measurement; Multiple Sclerosis; Outcomes; Spasticity
Source


This Article is Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  87 Hits

Copyright

© M.S. Views & News

87 Hits

Computational Drug Repurposing Algorithm Targeting TRPA1 Calcium Channel as a Potential Therapeutic Solution for Multiple Sclerosis.

Author information

1Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania.2Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania. This email address is being protected from spambots. You need JavaScript enabled to view it. for Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstrasse 17, 1090 Vienna, Austria.

Abstract

Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system (CNS) through neurodegeneration and demyelination, leading to physical/cognitive disability and neurological defects. A viable target for treating MS appears to be the Transient Receptor Potential Ankyrin 1 (TRPA1) calcium channel, whose inhibition has been shown to have beneficial effects on neuroglial cells and protect against demyelination. Using computational drug discovery and data mining methods, we performed an in silico screening study combining chemical graph mining, quantitative structure-activity relationship (QSAR) modeling, and molecular docking techniques in a global prediction model in order to identify repurposable drugs as potent TRPA1 antagonists that may serve as potential treatments for MS patients. After screening the DrugBank database with the combined generated algorithm, 903 repurposable structures were selected, with 97 displaying satisfactory inhibition probabilities and pharmacokinetics. Among the top 10 most probable inhibitors of TRPA1 with good blood brain barrier (BBB) permeability, desvenlafaxine, paliperidone, and febuxostat emerged as the most promising repurposable agents for treating MS. Molecular docking studies indicated that desvenlafaxine, paliperidone, and febuxostat are likely to induce allosteric TRPA1 channel inhibition. Future in vitro and in vivo studies are needed to confirm the biological activity of the selected hit molecules.
PMID: 31480671 DOI: 10.3390/pharmaceutics11090446

This Article is Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  85 Hits

Copyright

© M.S. Views & News

85 Hits

Aerobic Exercise Helps Multiple Sclerosis—But How and How Fast?

Aerobic Exercise Helps Multiple Sclerosis—But How and How Fast?
By Rebecca Spain, M.D., MSPH 

Rebecca Spain, M.D., MSPH
It is generally accepted that aerobic exercise is good for cardiovascular health, improving mitochondrial adenosine triphosphate (ATP) production in skeletal muscles, and reducing risks of other chronic diseases. We also know that aerobic exercise improves cognitive function and reduces fatigue—this holds true for people with Multiple Sclerosis (MS) who often are affected by these consequences of their disease. Less known is how quickly improvements may develop in these functions as a result of participating in aerobic physical activity, nor have the cerebral mechanisms underlying such clinical improvements been identified.

MS is an autoimmune neuro-inflammatory disease of the central nervous system (CNS) that results in demyelination of axons and neurodegeneration. The underlying pathophysiology of MS is complex with inflammatory, oxidative and neurodegenerative pathologies found. MS typically starts as relapsing-remitting cycles with bouts of neurological dysfunction corresponding to CNS inflammation followed by complete or partial recovery of function. A minority of affected individuals have a progressive course from onset. MS symptoms can include weakness, sensory loss, imbalance, incoordination, vision loss, brainstem dysfunction manifesting in double vision and difficulty swallowing, muscle spasticity and neurogenic bladder. “Silent” symptoms of cognitive dysfunction and fatigue can be some of the most disabling.

While the underlying cause of MS is unknown, genetic and environmental risk factors have been identified. Comorbid conditions include obesity, hypertension, diabetes, cardiovascular disease and hyperlipidemia; these risk factors are associated with an accelerated pace of disability accumulation. The “vascular” comorbid conditions can all be prevented or improved by aerobic exercise, suggesting a contribution to disease management that is independent of the immune-mediated therapies most people with MS take. This led us to hypothesize that aerobic exercise may have a unique role in treating MS, and the mechanism may be mediated through improved ATP production.

In our study, as reported in the July 2019 issue of Medicine & Science in Sports & Exercise®, my colleagues and I demonstrated that a high-intensity aerobic exercise program in a mild-to-moderately disabled MS population typically results in rapid cardiovascular improvement and also produced expected benefits of improved V?O2max, peak work, etc. These benefits were achieved despite the subjects’ physical limitations and underlying fatigue. Further, the MS cohort (n=10) also demonstrated significant improvements in cognitive processing speed and reductions in cognitive fatigue compared to a control MS stretching group (n=7). While the exercise training was safe and well-tolerated by the subjects, a re-emergence of exercise-induced syncope served as a reminder that prudence of supervision is essential when initiating a high-intensity exercise program in patients with MS.

We used phosphorous magnetic resonance spectroscopy (31PMRS) to evaluate individual ATP peaks and the rate-constant of phosphocreatine recovery in tibialis anterior muscles. These measures were taken prior to and following the eight-week protocol. As expected, only the aerobic exercisers demonstrated improvements. When using 31PMRS for investigating ATP changes in the brain, only ATP peaks can be detected; we found no pre- to post-intervention changes for this measure in either cohort. However, a cross-sectional comparison of MS and healthy controls did show a significantly higher level of in-the-brain measures for phosphocreatine to inorganic phosphate peak in the MS group. A larger or longer exercise study will help determine if aerobic exercise increases brain ATP levels.

In sum, aerobic exercise benefits people with MS, even if only a brief high-intensity program. Such an intervention can improve cognition, reduce cognitive fatigue and promote cardiovascular benefits. 31PMRS may prove a useful technique to quantitate the benefits of aerobic effects on ATP levels, and this technology may help us design the optimal combination therapies for this complex disease


Continue reading

...................................................................................

Stay Informed. Register to receive 
'The MS BEACON' e-Newsletter Click here

.................................................................................................


Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  127 Hits

Copyright

© M.S. Views & News

127 Hits

Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS

Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS

Published: Sep 04, 2019

Sept. 4, 2019 05:00 UTC
Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder (NMOSD)New data provide insights into neurofilament light chain (NfL) levels as a potential biomarker for predicting Multiple Sclerosis (MS) disability progression; new longer-term Ocrevus data of more than six years show reduction of disability progression in relapsing and Primary Progressive MSBreadth of data reinforce Genentech's commitment to following the science to gain a better understanding of complex nervous system disorders
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data across its neuroscience portfolio will be presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from September 11-13 in Stockholm. Presentations include complete Phase III results from the SAkuraStar study investigating satralizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD), and new Multiple Sclerosis (MS) research, which provides insights into disease progression, including data from Ocrevus®(ocrelizumab) trials that advance understanding of neurofilament light chain (NfL) levels as a potential biomarker for predicting disability outcomes. Additionally, longer-term data of more than six years to be presented continue to show consistent safety and efficacy outcomes for patients treated with Ocrevus earlier.
“Disorders of the nervous system are some of the most complex and difficult to treat, and we have increased our commitment in neuroscience to advance care and scientific understanding for conditions such as Multiple Sclerosis and neuromyelitis optica spectrum disorder. Data being presented at ECTRIMS include positive Phase III results for satralizumab as a monotherapy, taking a novel approach to treating neuromyelitis optica spectrum disorder, and new insights using biomarkers to identify disease progression in Multiple Sclerosis,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “Similar to our approach with Ocrevus in Multiple Sclerosis, targeting B cells as a key driver of disease, we aim to offer satralizumab as a highly effective treatment option in neuromyelitis optica spectrum disorder, targeting the interleukin-6 receptor.”
About neuromyelitis optica spectrum disorder (NMOSD)
Complete pivotal data from the SAkuraStar study investigating satralizumab as a subcutaneous monotherapy compared to placebo for the treatment of NMOSD will be presented. The primary and subgroup analyses show that satralizumab significantly reduces the risk of relapse in patients who were seropositive for aquaporin-4 auto-antibodies (AQP4-IgG), as well as the overall intention-to-treat (ITT) population representative of NMOSD patients. Satralizumab also demonstrates a similar safety profile compared to placebo.
NMOSD is a rare, lifelong and debilitating autoimmune disease of the central nervous system commonly misdiagnosed as MS. It is associated with pathogenic AQP4-IgG auto-antibodies that target and damage a specific cell type, called astrocytes, resulting in inflammatory lesions of the optic nerve(s), spinal cord and brain. Through the use of a diagnostic biomarker test, the majority of people with NMOSD are identified as AQP4-IgG seropositive and tend to experience a more severe disease course; however, as many as one-third of those with NMOSD are AQP4-IgG seronegative. At ECTRIMS, two analyses of U.S. healthcare insurance claims databases will be presented that reflect the low utilization of AQP4-IgG diagnostic testing and the subsequent frequency of misdiagnosis of NMOSD patients.
Additionally, two pre-clinical in-vitro models will be presented that show satralizumab reduces the degradation of the blood brain barrier, supporting evidence of its multi-faceted mechanism of action.

...................................................................................

Stay Informed. Register to receive 
'The MS BEACON' e-Newsletter Click here

.................................................................................................

This Article is Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  125 Hits

Copyright

© M.S. Views & News

125 Hits

Medical Marijuana (Cannabis) FAQs

#MedicalMarijuana


What is cannabis?

Cannabis is a flowering plant with fibrous stalks. The leaves, flowers, and roots are used for medicinal purposes. On the mature plant, the leaves and flowers are covered with trichomes - tiny glands of resinous oil containing cannabinoids and terpenes that, when consumed, can provide physical and psychoactive effects. 

What is medical cannabis?

Also called “medical marijuana,” medical cannabis is cannabis and cannabinoids (chemical compounds in the plant) that can be medically recommended to treat certain conditions and symptoms, such as nausea and vomiting associated with chemotherapy, and pain that can be associated with numerous conditions. 

What are cannabinoids?

Cannabinoids are the chemical compounds secreted by cannabis flowers. There are also compounds called terpenes – chemical compounds that give cannabis its unique aroma. The concentrations and combinations of the cannabinoids and terpenes vary from plant to plant and among the different strains of cannabis. When inhaled, consumed as an edible, or used on the skin as a topical preparation, the cannabinoids bind to cannabinoid docking sites or receptors in the human body and alter nerve transmission in the brain. 

What is the difference between THC and CBD?





........................................................................................................
This Article is Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  165 Hits

Copyright

© M.S. Views & News

165 Hits

Join us (in Columbus, OH) for a Special Roundtable discussion: "MS Conversations NOW" , with Aaron Boster, MD and an MS Patient Advocate

Join us (in Columbus, OH) for a Special Roundtable discussion: "MS Conversations NOW" , with Aaron Boster, MD and an MS Patient Advocate
REGISTRATION NOW open for MS event called "MS Conversations NOW"

RSVP for this Special RoundTable discussion with two special people (both quite involved in the MS Community). 

Event taking place in Columbus, OH on Thursday - Dec 5th.. –
Aaron Boster, MD and I (Stuart Schlossman), will compassionately face-off with each other in a new styled round table discussion. 

Listen as they discuss hot MS topics that affect so many, including what patients need to know more, from their neuro teams and what the Neurologists need to learn more, from the MS patient community, during their short office visits so that needs can be met. 

Other hot topics being discussed from the Physician standpoint and the Patient's perspective, include disease Progression, MRI, MS Relapse, symptoms, and others topics as showing in the banner seen below.

If you are in the Central Ohio area, we hope you can join us on 12/5 for this dinner event.
 Rsvp here: www.events.msvn.org, for MS Conversations Now.

During this roundtable discussion we will also be asking the audience for their feedback, opinions and questions, with the intent on getting many attendees included into our discussion. 

Yes, Join us for "MS Conversations NOW" in Columbus, on December 5th, 2019.  Click here to view the program Flyer. 
Then RSVP by clicking the link showing on that flyer or simply by clicking here (then scrolling down on page) 





If you plan to attend, and want to be involved in the dialogue, 
send an email to: This email address is being protected from spambots. You need JavaScript enabled to view it.

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  74 Hits

Copyright

© M.S. Views & News

74 Hits

AAN issues guideline on vaccines and MS

AAN issues guideline on vaccines and MS
source: MS Foundation


August 29, 2019
Can a person with Multiple Sclerosis get regular vaccines? According to a new guideline, the answer is yes. The guideline, developed by the American Academy of Neurology, recommends that people with MS receive recommended vaccinations, including yearly flu shots. The guideline is endorsed by the Consortium of Multiple Sclerosis Centers.

In addition, the guideline recommends that people with MS should make sure their doctor or care team knows what MS medications they are using before receiving vaccinations. There is some evidence that shows that certain vaccinations may not work as well with certain MS medications. Clinicians should recommend against using live-attenuated vaccines in people with MS receiving ISIM therapies.

The guideline recommends that people experiencing an MS flare consult their doctor before receiving vaccinations. They may want to consider waiting until the flare has passed before receiving vaccinations.

Finally, the guideline states that some vaccines might not work well enough to prevent infection for some people with MS who take certain MS medications. However, it is recommended that people still work with their care team to maintain their regular recommended vaccinations, including the flu shot.

The guideline is published in Neurology, the medical journal of the AAN.
...................................................................................

Stay Informed. Register to receive 
'The MS BEACON' e-Newsletter, Click here

............................................................................................

This Article is Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  166 Hits

Copyright

© M.S. Views & News

166 Hits

Infusion Treatments: Benefits and Side Effects


Multiple Sclerosis (MS) is an autoimmune disease that affects the central nervous system (CNS).
With MS, your immune system mistakenly attacks your nerves and destroys myelin, their protective coating. If left untreated, MS can eventually destroy all of the myelin surrounding your nerves. Then it may start to harm the nerves themselves.
There’s no cure for MS, but there are several types of treatments. In some cases, treatment can slow the pace of MS. Treatment can also help ease symptoms and reduce potential damage done by MS flare-ups. Flare-ups are the periods when you have symptoms.
However, once an attack has started, you may need another type of medication called a disease modifier. disease modifiers can change how the disease behaves. They can also help slow the progression of MS and reduce flare-ups.
Some disease-modifying therapies come as infused medications. These infusion treatments may be especially helpful to people with aggressive or advanced MS. Read on to learn more about these medications and how they help treat MS.
Q&A: Administering infusion treatments

Q: How are infusion treatments given?

A: These drugs are injected intravenously. This means you receive them through your vein. However, you don’t inject these medications yourself. You can only receive these drugs from a healthcare provider in a healthcare facility.

The Healthline Medical Team

Infusion treatment drugs

Today there are four infusible drugs available to treat MS. However, we are only showing three as the fourth is not used any longer (being a dangerous chemo-therapy drug)

Alemtuzumab (Lemtrada)

Doctors give alemtuzumab (Lemtrada) to people who haven’t responded well to at least two other MS medications.
This drug works by slowly reducing your body’s number of T and B lymphocytes, which are types of white blood cells (WBCs). This action may reduce inflammation and damage to nerve cells.
You receive this drug once per day for five days. Then one year after your first treatment, you receive the drug once per day for three days.

Natalizumab (Tysabri)

Natalizumab (Tysabri) works by stopping the damaging immune cells from entering your brain and spinal cord. You receive this drug once every four weeks.

Ocrelizumab (Ocrevus)

Ocrelizumab is the newest infusion treatment for MS. It was approved by the Food and Drug Administration (FDA) in 2017.
Ocrelizumab is used to treat relapsing or Primary Progressive forms of MS. In fact, it’s the first drug approved to treat Primary Progressive MS (PPMS).
This medication is thought to work by targeting the B lymphocytes that are responsible for myelin sheath damage and repair.
It’s initially given in two 300-milligram infusions, separated by two weeks. After that, it’s given in 600-milligram infusions every six months. 
Side effects of the infusion process



........................................................................................................
This Article is Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  124 Hits

Copyright

© M.S. Views & News

124 Hits

Unusual Symptoms of MS - Take a look

MS: Strangest symptoms From Head to Toe

Extreme fatigue, clumsiness, weird prickly sensations, sluggish thinking, wonky vision -- these are classic and common first symptoms of Multiple Sclerosis, or MS. But the expected stops here. Damage to the central nervous system, aka your brain and spinal cord, is what causes these symptoms. That’s a wide range of functions that affect many different people. So it can show up in some strange and varied ways.

Trapped in a Bear Hug

It’s not a warm and cozy kind of hug. Called banding, this MS symptom feels like something’s squeezing you firmly about the chest and won’t let go. It can strike anywhere between your waist and neck, or just on one side. You might have pain or breathlessness. It happens when damage from the disease blocks or garbles the messages from your nerves. Spasms in the muscles between your ribs trigger the tightness. It often passes on its own.

Out-of-Control Laughing or Sobbing

Pseudobulbar affect, also called PBA or emotional incontinence, prompts random outbursts of tears or laughter that have nothing to do with how you feel. Nerve damage in the part of your brain that controls emotions can cause your responses to get all mixed up. You might worry about it happening when you’re in public, or in a serious setting. The FDA has approved a drug to treat PBA. Antidepressants can help, too.

Shocking Face Flashes

Nerve damage can trigger trigeminal neuralgia, a burning, stabbing, or shock-like pain in your cheek or jaw. It might fade fast or linger for a few minutes. Though rare, it can be a first symptom of MS. You might feel it come on as a tingle, numbness, or ache on one side of your face, like dental pain. Anticonvulsant meds such as carbamazepine, lamotrigine (Lamictal), or oxcarbazepine (Oxteller XR, Trileptal) can help.

An Itch You Can’t Scratch

It’s the itch that isn’t. A sudden, intense tingle crops up out of the blue, anywhere on your body. But there’s no skin irritation or allergy to scratch or apply rash cream to. This kind of itch doesn’t stem from your skin. Dysesthetic itching is a nerve-related sensation that passes quickly. It’s treatable with meds for epilepsy. Carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Tegretol-XR), gabapentin (Horizant, Neurontin), and phenytoin (Dilantin, Phenytek) are a few.

Fiery Feet

Dysesthesia is an unpleasant “altered” sensation like burning, prickly pins-and-needles, numbness, and creepy-crawlies in any part of your body. For example, your feet might suddenly feel scalded, with no heat source -- or damage -- at all. Your brain gets distorted nerve signals, so it struggles to relate to something it recalls or imagines. Sometimes it comes up with some pretty crazy stuff. You can treat the weird feelings with nerve pain meds. 

More to read: 
Swallowing difficulties, Spinal Tingling sensations, Blurred Vision, Optical illusions, Facial Pains, Migraines, Hearing Problems, Vertigo,



This Article is Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  140 Hits

Copyright

© M.S. Views & News

140 Hits

Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies

Aug 30, 2019


In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio®*(teriflunomide) in patients with relapsing forms of MS (RMS)[1]
Key secondary endpoints of delaying time to confirmed disability progression were also met[1]; additional secondary endpoints will be presented at ECTRIMS

#Ofatumumab, a potent, fully-human antibody targeting CD20 positive B-cells, delivered sustained efficacy with a favorable safety profile[1]

#Novartis plans to initiate submissions to health authorities by end of 2019. If approved, ofatumumab will potentially become a treatment for a broad RMS population and the first B-cell therapy that can be self-administered at home

Basel, August 30, 2019 – Novartis, a global leader in neuroscience, today announced positive results for ofatumumab (OMB157) from the Phase III ASCLEPIOS I and II studies. In both head-to-head studies, ofatumumab demonstrated superiority over Aubagio®* (teriflunomide) in patients with relapsing forms of Multiple Sclerosis (RMS)[1]. The ASCLEPIOS studies investigated the efficacy and safety of monthly subcutaneous ofatumumab 20mg versus once daily oral Aubagio® 14mg in adults with RMS[3],[4].

Both studies met the primary endpoints where ofatumumab showed a highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as the annualized relapse rate (ARR)[1]. Key secondary endpoints of delaying time to confirmed disability progression were also met[1]. The top line results of the Phase III ASCLEPIOS studies will be presented at the 35thCongress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), taking place September 11–13, 2019, in Stockholm, Sweden. Overall ofatumumab, a potent, fully-human antibody targeting CD20 positive B-cells, delivered sustained efficacy with a favorable safety profile. The safety profile of ofatumumab as seen in the ASCLEPIOS studies is in line with the observations from Phase II results. Novartis plans to initiate submissions to health authorities by end of 2019.

“It is clear that early initiation of highly effective treatment for MS improves long-term outcomes, and there is a high need for potent, safe, and convenient therapy that can be used to treat MS from the start,” said Professor Stephen L. Hauser, Director of the UCSF Weill Institute for Neurosciences. “The results from ASCLEPIOS are wonderful news for patients who would like to take an effective B-cell therapy with low requirement for monitoring, avoiding visits to an infusion center.”

“Ofatumumab, if approved, could be a highly attractive treatment option for a broad RMS patient population, including early MS,” said John Tsai, Head Global Drug Development and Chief Medical Officer, Novartis. “The powerful study results are a reflection of our commitment to reimagine MS treatment at all stages of the disease.”

About ASCLEPIOS

Continue reading

.
This Article is Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  91 Hits

Copyright

© M.S. Views & News

91 Hits

Small Study Finds that a Diet that Improves Cholesterol Levels May Reduce MS-Related Fatigue


August 16, 2019

SUMMARY
In a small pilot study, researchers found that a specific diet that improved participants’ lipid profile (levels of blood fats, including cholesterol and triglycerides) and reduced body weight also led to reductions in MS-related fatigue.If results are confirmed by larger studies, this may offer another strategy for treating MS fatigue. At least one follow-up study is underway.Dr. Kelly Fellows Maxwell and others at State University of New York, Buffalo, and Dr. Terry Wahls and others at the University of Iowa published their findings in PLOS ONE (published online June 18, 2019).DETAILS
CLICK here to continue reading



This Article is Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  344 Hits

Copyright

© M.S. Views & News

344 Hits
 
 

Follow Us on Twitter

Follow Us On Twitter - Image